GlassScriptPhysician profile
Yuliya Malayev
NPI 1720342009
$2,951.48
in general payments reported to CMS, 2019-2025
31 companies · $453 in 2025
The $453 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $132 · 2021: $313 · 2022: $819 · 2023: $587 · 2024: $457 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.66 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.37 | 2019-2024 | |
| Astellas Pharma US INC | $291.72 | 2021-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $261.73 | 2021-2025 | |
| Gynesonics, INC. | $259.50 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $229.86 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Aspira Women'S Health INC | $172.34 | 2019-2024 | Ova1 |
| Sumitomo Pharma America, INC. | $158.33 | 2023-2024 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $140.39 | 2019-2025 | Slynd |
| Daiichi Sankyo INC. | $106.45 | 2022-2025 | Injectafer |
| Organon LLC | $77.08 | 2022-2025 | Jada System, Nexplanon |
| Pfizer INC. | $74.99 | 2022-2024 | |
| Myovant Sciences INC. | $67.11 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $51.88 | 2020-2022 | |
| Coopersurgical, INC. | $46.97 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $43.02 | 2025 | Zurzuvae |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.32 | 2019-2023 | Balcoltra |
| Therapeuticsmd, INC. | $38.76 | 2019-2021 | |
| Duchesnay USA Incorporated | $37.89 | 2019 | |
| Exact Sciences Corporation | $37.88 | 2023-2024 | Cologuard Collection Kit |
| Millicent US INC | $37.31 | 2025 | Femlyv |
| Shield Therapeutics INC | $36.30 | 2024 | |
| Ascend Therapeutics US, LLC | $28.51 | 2021-2023 | |
| Baxter Healthcare | $21.88 | 2025 | Tisseel |
| Medtronic, INC. | $19.85 | 2023 | Truclear |
| Merck Sharp & Dohme LLC | $18.40 | 2021 | |
| Scynexis, INC. | $18.09 | 2022 | |
| Agile Therapeutics, INC. | $17.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2023 | Seglentis |
| Allergan, INC. | $15.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.76 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuliya Malayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.